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or (2) the intrinsic pathway, induced by a number of intra-
cellular signals, including oxidative stress, genotoxic stress, 
UV irradiation, and growth factor withdrawal. The signaling 
pathways that ultimately lead to apoptosis are highly regu-
lated by overlapping mechanisms, and include a number of 
pro-apoptotic proteins (e.g., Bim, Bid, Bad, Bax, Bak, and 
PUMA, etc.) as well as anti-apoptotic proteins (e.g., Bcl-2, 
Bcl-XL, XIAP, and FLIP, etc.). Some forms of apopto-
sis are dependent on depolarization of the mitochondrial 
outer membrane with release of mitochondrial contents 
(e.g., cytochrome C, SMAC) that promulgate the apoptotic 
signal, whereas other forms are mitochondria-independent. 
In addition, some but not all forms of apoptosis are depend-
ent on the activity of a family of proteins called caspases 
(cysteine-dependent aspartate-directed proteases), which 
can act either as regulators or effectors of apoptosis.
Many controversies remain in the understanding of 
HIV-induced apoptosis. For instance, does apoptosis occur 
predominately in infected or uninfected, so called bystander, 
cells? Which of the many pro-apoptotic mechanisms 
proposed to account for CD4 T cell losses over time pre-
dominate in clinical HIV disease? And most importantly, 
why does HIV induce apoptosis in the host target cells? 
Nearly 20 years of research in HIV-induced apoptosis has 
largely failed to find definitive answers to these fundamental 
questions.
We refer the reader to a number of recent reviews that 
summarize the latest understanding of the hypothesized pro-
apoptotic mechanisms and effects of HIV, a discussion of 
which is beyond the scope of this manuscript [2, 3]. How-
ever, it is increasingly clear that the predominate reason 
HIV induces apoptosis in the host target cell is, paradoxi-
cally, to ensure viral replication. In fact, HIV replication is 
(1) increased in immortalized T cell lines induced to express 
pro-apoptotic proteins (FasL, FADD [Fas-associated death 
Abstract Past efforts at curing infection with the human 
immunodeficiency virus (HIV) have been blocked by the 
resistance of some infected cells to viral cytopathic effects 
and the associated development of a latent viral reservoir. 
Furthermore, current efforts to clear the viral reservoir by 
means of reactivating latent virus are hampered by the lack 
of cell death in the newly productively infected cells. The 
purpose of this review is to describe the many anti-apoptotic 
mechanisms of HIV, as well as the current limitations in the 
field. Only by understanding how infected cells avoid HIV-
induced cell death can an effective strategy to kill infected 
cells be developed.
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Introduction
The loss of CD4 T cells during acute and chronic HIV 
infection occurs predominately through aberrant induction 
of cell death, including through apoptosis. Apoptosis is one 
type of a growing number of related mechanisms for pro-
grammed cell death [1]. It is characterized phenotypically 
by cell membrane blebbing, cellular shrinking, and nuclear 
and DNA fragmentation. Apoptosis has classically been 
categorized as occurring via one of two main pathways: 
(1) the extrinsic pathway, induced by a death ligand (tumor 
necrosis factor [TNF], Fas ligand, or TNF-related apoptosis 
inducing ligand [TRAIL] engagement of a death receptor; 
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domain protein], and p53); (2) decreased in cells overex-
pressing anti-apoptotic proteins (Bcl-2, FLIP [FLICE-
inhibitory protein], Bcl-XL, and XIAP [X-linked inhibitor 
of apoptosis protein]); (3) decreased in cells with knock-
down of pro-apoptotic proteins (Bax and FADD); and 
(4) decreased in the setting of inhibition of caspase 3 activity 
[4–6]. Importantly, treatment with the HIV envelope protein 
Gp120 or expression of Casp8p41 (a unique cleavage frag-
ment of procaspase 8 generated by HIV protease), both of 
which are associated with HIV-induced apoptosis, increases 
NF-κB-dependent HIV-LTR (long terminal repeat) tran-
scription compared to untreated cells or cells treated with 
control proteins [7, 8]. This suggests that the critical link 
between HIV-induced apoptosis and replication is in activa-
tion of NF-κB, through a caspase 8-dependent mechanism, 
a survival mechanism that has been co-opted by a number 
of other viruses [9].
The purpose of this review is to summarize the current 
understanding of another fundamental question regarding 
HIV-induced apoptosis: How does HIV prevent death in the 
infected host cell long enough to promote viral replication 
and spread and establishment of the latent viral reservoir? 
This question is of paramount importance. If one could 
determine how HIV prevents premature infected cell death, 
then inhibiting this effect could lead towards a viral eradica-
tion strategy aimed at killing all infected cells, and eventual 
cure of the infection.
Grains of salt
Studying HIV-induced apoptosis has several notable limi-
tations to which the readers’ attention must be drawn, 
as inferences made on experimental data are inherently 
difficult. First, phenotypic and molecular definitions of 
apoptosis have evolved significantly over time, and there 
is increasing recognition of overlap between alternate 
mechanisms of cell death, including necrosis, necroptosis, 
paraptosis, autophagy, and others [10, 11]. Second, until 
recently, small animal models of HIV are limited in 
pathologic relevance, and non-human primate models 
are both financially and temporally expensive. Further-
more, access to relevant human samples is often limited 
by invasiveness and patient discomfort. Therefore, much 
of the experimental data relies on in vitro or ex vivo 
cellular or tissue models, which necessarily do not mimic 
the immunologic complexity of an HIV-infected person. 
Third, these models often rely on exogenous administra-
tion, or forced overexpression of HIV-associated proteins; 
however, neither the biologically relevant intracellular 
nor tissue concentrations of the HIV-associated proteins 
are agreed upon. Other investigators infect cells with 
single-deletion, replication-deficient mutants, making 
the results of these models of questionable physiologic 
relevance. Finally, measurement of markers of apopto-
sis in concert with meaningful markers of HIV infection 
cannot reliably differentiate between apoptotic-and-
infected or apoptotic-and-uninfected cell deaths. This 
is because cells undergoing apoptosis activate proteases 
and nucleases that degrade cellular targets of laboratory 
methods to detect infection, i.e., antibodies to detect HIV-
associated proteins, and complementary nucleic acids to 
detect HIV RNA or cDNA.
Lessons from viral kinetics
In vitro models of HIV infection indicate (and mathemati-
cal models of viral decay in HIV-infected patients who 
initiate antiretroviral therapy confirm) that the single round 
life cycle of HIV in productively infected cells is 2–3 days 
[12–14]. This suggests that in productively infected cells, 
HIV-associated antiapoptotic mechanisms need not be par-
ticularly robust or long-lasting. Furthermore, individual 
CD4 T cells are generally infected by a single HIV virion, 
and upon cell death release 25–200 progeny virions per cell 
[14]. This would suggest that HIV proteins present early 
in the infection cycle, which are derived solely from the 
single infecting virion, would exist in relatively low con-
centrations. However, after transcription of viral mRNA and 
translation of viral proteins in preparation for virus assem-
bly and release, the same proteins would be expressed at a 
relatively much higher intracellular concentration. As will 
be discussed below, this may provide a framework upon 
which to interpret seemingly contradictory results obtained 
in studies describing both pro- and anti-apoptotic effects of 
individual HIV-associated proteins.
Early events in the HIV virus life cycle
Binding of the HIV envelope protein Gp120 to the host 
cell CD4 receptor induces a conformational change in the 
Gp120, allowing binding to the cellular co-receptor, prin-
cipally CCR5 or CXCR4. This attachment is followed by 
fusion of the viral and host membranes mediated by Gp41, 
and release of viral genetic material and a number of virus-
associated proteins into the cytoplasm of the cell. The viral 
proteins released during uncoating of the virus include 
reverse transcriptase, structural proteins, and the viral 
accessory proteins Nef, Vif, and Vpr. Since Gp120 ligation 
of the CD4 receptor and co-receptors induces pro-apoptotic 
signals through a number of pathways [2], and has been 
implicated in uninfected bystander T cell apoptosis, it is 
likely that these early viral-associated proteins protect the 
newly infected cell from premature cell death.
3357Anti-apoptotic mechanisms of HIV 
1 3
For instance, Vpr is an HIV-accessory protein present 
in high copy number in mature virions, and is released 
into the cytoplasm upon uncoating of the infecting virus; 
it has been variously described to have both pro- and anti-
apoptotic properties based on the infection model and 
protein concentration [2]. Jurkat T cells stably express-
ing low levels of Vpr are resistant to both intrinsic and 
extrinsic apoptotic signals compared to control cells, and 
this is associated with increased Bcl-2 and decreased Bax 
expression [15]. Jurkat cells infected with HIV have a 
transient resistance to apoptosis induced by tumor necro-
sis factor (TNF) and cyclohexamide at 48 h after infec-
tion, which reverses at 72 h [16]. This apoptotic-resistant 
phenotype of HIV infection is dependent on Vpr expression, 
and occurs predominately in productively infected cells as 
opposed to bystander cells [16]. However, in later stages 
of infection, the opposite effect is seen, in that apoptosis 
in the absence of additional stimuli is increased in produc-
tively infected Jurkat cells compared to uninfected cells. 
Furthermore, inhibition of Vpr using antisense oligodeox-
ynucleotides reverses this increased spontaneous apoptosis 
[16]. Similar results are demonstrated in HIV-infected pri-
mary cells. These experiments show that Vpr expressed 
in low levels early in infection are anti-apoptotic, but in 
higher concentrations later in infection the same protein 
is pro-apoptotic.
Vpr also induces G2 cell cycle arrest in infected cells, 
one effect that has been implicated in HIV-induced apopto-
sis. However, early in infection, the HIV-accessory protein 
Vif induces proteosomal degradation of Vpr, similar to Vif’s 
function of inducing degradation of the ABOBEC3G host 
restriction factor. Therefore, expression of Vif early in the 
infection cycle may delay Vpr-induced G2 cell cycle arrest, 
allowing for early infected cell survival [17].
Nef is a polyfunctional HIV-associated protein that 
downregulates the expression of a number of cell surface 
receptors on the infected cell, including MHC Class I mole-
cules and CD28. In addition, Nef expression, and to a lesser 
extent Vpu and Gp120, in HIV-infected cells decreases CD4 
surface expression, decreasing the likelihood of superin-
fection with a second virus [18]. Superinfection increases 
infected cell apoptosis [18]; therefore, this may represent 
another antiapoptotic mechanism early in the viral life 
cycle. Nef also directly binds to p53 through its N-terminal 
end and decreases the intracellular half life of p53 and 
p53-dependent transcriptional activation in in vitro HIV 
infection [19]. As additional evidence of Nef’s anti-apoptotic 
effects, endogenous expression of Nef in MOLT-4 cells pro-
tects against p53-dependent UV-induced apoptosis. Since 
p53 signaling has been implicated in apoptosis induced by 
the HIV Gp120 [20], it is possible that early expression of 
Nef inhibits pro-apoptotic signals induced by viral attach-
ment and entry.
A number of cellular proteins, in addition to the viral 
proteins discussed above, are packaged into and accompany 
infecting HIV virions [21], and could have an early anti-
apoptotic effect. For instance, the cellular protein kinase 
mitogen-activated protein kinase 1 (MAPK1), also known 
as extracellular signal-regulated kinase 2 (ERK2), is incor-
porated into the virion, and has been shown to be necessary 
for nuclear translocation of the HIV pre-integration com-
plex [22]. Phosphorylation by MAPK1/ERK2 regulates 
the activity of a number of apoptotic regulatory proteins, 
and inhibition of MAPK1/ERK2 activity inhibits cellular 
proliferation and decreases survival [23]. It is possible that 
MAPK1/ERK2 incorporated into HIV virions could have a 
similar function in early stages of cellular infection with the 
virus, although this has not been directly studied. Additional 
examples of cellular proteins that are incorporated into HIV 
that have anti-apoptotic properties include heat shock pro-
tein 70 (Hsp70) and cyclophilin A [21].
A recent study published in Cell by Doitsh and colleagues 
has caused a true paradigm shift in the understanding 
of HIV-induced apoptosis, and so-called “bystander” apop-
tosis [24]. Using a model of ex vivo infection of human 
lymphoid tissue, they demonstrated that incomplete reverse 
transcription of the viral genetic material results in the accu-
mulation of cytotoxic DNA material, resulting in parap-
tosis (a form of apoptosis) of cells nonpermissive of viral 
replication. Therefore, bystander cells, instead of being 
truly uninfected, may be non-productively infected, and this 
condition of non-productive infection drives cell death. It is 
possible, then, that the ultimate fate of the early infected cell 
is dependent upon mechanisms that promote survival in the 
face of this cytotoxic insult, and may rely on the above-men-
tioned anti-apoptotic viral or cellular proteins that accom-
pany the infecting virion.
Latency
After reverse transcription of the viral genome and inte-
gration of the cDNA into the host genome, an important 
minority of cells enters a period of latent infection, 
defined by the absence of transcription of the viral 
message and production of viral proteins. This is in 
contrast to chronic infection, in which infected cells pro-
duce and release progeny virions, but do not succumb to 
HIV-induced cell death. The molecular determinants of 
HIV latency, including histone deacetylases [25] as tar-
gets for non-toxic viral activation, are the “Holy Grail” of 
current research efforts at novel viral eradication strate-
gies. X-linked inhibitor of apoptosis protein (XIAP), a 
member of the IAP family, inhibits apoptosis by directly 
inhibiting caspase 3 and caspase 9 activity, as well as 
activating JNK signaling [26]. One study suggests that 
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XIAP expression is increased in latently HIV-infected T 
cells compared to uninfected cells, and chemical inhibi-
tion of XIAP activity sensitizes the latently infected cells 
to apoptosis [27]. Similarly, we have observed decreased 
expression of procaspase 8 in central memory CD4 T cells, 
which serve as an in vivo latent viral reservoir (unpub-
lished observations). However, more research is needed in 
this area, as current in vitro models of latent HIV infec-
tion rely heavily on immortalized laboratory cell lines 
with integrated HIV virus, the relevance of which to in 
vivo viral latency is unclear.
Similarly, the chronically HIV-infected H9 T cell line 
exhibits a significantly altered apoptotic gene expres-
sion profile by microarray analysis compared to the unin-
fected parent cell line [5]. Infected H9 cells have increased 
expression of nine antiapoptotic and seven proapoptotic 
genes, and decreased expression of six antiapoptotic and 12 
proapoptotic genes, possibly contributing to cell survival in 
the setting of chronic infection. Chronically HIV-infected 
HUT78 T cells express less DAP kinase, p19ARF, p53, 
and p21WAF1, all proteins associated with death-receptor 
signaling, compared to uninfected control cells [28]. This 
is associated with increased resistance to FasL-mediated 
apoptosis in infected cells compared to control.
Late events in the HIV virus life cycle
A number of cellular activation signals and transcription 
factors, including NF-κB, can initiate the transcription of 
integrated viral message to begin the viral replication pro-
cesses. One of the first viral proteins produced following 
reactivation is Tat (transactivator of transcription), which 
further enhances transcription of viral genes by binding to 
the transactivation response element within the HIV-LTR. 
Endogenous expression of Tat in Jurkat T cells decreases 
apoptosis induced by TNF, FasL, TRAIL, and T cell 
receptor ligation compared to control cells [29, 30]. Fur-
thermore, Jurkat T cells transfected with a Tat-expression 
vector are less susceptible to apoptosis induced by subse-
quent infection with HIV compared to mock transfected 
cells. A number of mechanisms have been proposed to 
account for Tat’s anti-apoptotic effects. Endogenous 
expression of Tat in HeLa, Jurkat T cells, and PBMCs 
results in increased Bcl-2 expression compared to control 
cells [31, 32]. This is likely a direct transcriptional acti-
vation, as the C-terminal end of Tat binds to two regions 
in the Bcl-2 promoter, whereas the N-terminal end of 
Tat is required for HIV-LTR transactivation [32]. Also, 
picomolar concentrations of exogenous Tat are sufficient 
to increase Bcl-2 expression in treated cells compared 
to untreated cells [31]. One study indicated that endog-
enous expression of Tat in two immortalized cell lines of 
non-lymphoid origin (COS and H1299) is associated with 
increased ubiquitination and degradation of Tip60, a pro-
apoptotic protein involved in the DNA damage response 
[33]. This confers resistance to apoptosis induced by 
actinomycin D in these cells. Jurkat T cells infected with 
HIV for 14 days express less Tip60 and are more resistant 
to actinomycin D-induced apoptosis compared to unin-
fected cells. However, the in vivo relevance of this poten-
tial anti-apoptotic mechanism is not known.
c-FLIP (FLICE-inhibitory protein) is a cellular regulator 
of apoptosis that inhibits caspase 8 and 10 activation at the 
DISC. Endogenous expression of HIV-1 Tat in Jurkat T 
cells results in increased c-FLIP expression and a TRAIL-
resistant phenotype compared to control cells [34]. c-FLIP 
expression was not different between PBLs isolated from 
HIV-infected and HIV-uninfected subjects in one small 
study [35]. However, c-FLIP expression was found to be 
significantly increased in PBLs from slow- or non-progres-
sive HIV-infected subjects compared to chronic progressive 
HIV-infected subjects [36].
As mentioned above, Vpr expression induces G(2)/M cell 
cycle arrest. Coincident with this cell cycle arrest, Vpr also 
induces expression of survivin in HIV-infected T cells [37]. 
Survivin is another member of the IAP family, which inhibits 
apoptosis by binding to XIAP and increasing XIAP’s 
stability against proteosomal degradation, and by sequester-
ing SMAC/Diablo from interacting with XIAP [38]. Induction 
of survivin expression by Vpr may then delay HIV-induced 
mitochondrial dependent apoptosis. This effect may be 
cell-type dependent, since Vpr expression in monocytes 
downregulates the expression of another member of the IAP 
family, c-IAP1, possibly contributing to Vpr’s pro-apoptotic 
effects [39].
Reactive oxygen species have been implicated in HIV-
induced apoptosis. The HIV envelope gene also encodes 
for a viral homologue of the human glutathione peroxidase 
(GPX) [40]. HIV GPX-transfected cells are resistant to 
apoptosis induced by exogenous ROS. Interestingly, HIV 
GPX sequence analysis from infected patients revealed that 
HIV long-term non-progressors had a decreased frequency 
of loss of function mutations in the GPX gene compared to 
patients who had progressed to AIDS, suggesting an in vivo 
antiapoptotic effect of functional GPX expression.
Bad (bcl-associated death promoter protein) is a cellular 
protein that in a dephosphorylated state binds to anti- 
apoptotic proteins, allowing unopposed Bax/Bak dependent 
mitochondrial depolarization and resulting apoptosis. Infec-
tion of Jurkat T cells with an HIV pseudovirus containing 
wild-type Nef results in significantly less apoptosis over 
time than infection with a pseudovirus containing a mutant 
Nef [41]. This anti-apoptotic effect of Nef was associated 
with p21-activated kinase-dependent phosphorylation and 
inactivation of Bad.
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Differential effects in myeloid cells
Myeloid lineage cells, including monocytes and 
macrophages, by virtue of expression CD4 and the HIV-
coreceptor CCR5, are permissive of HIV infection, but are 
largely spared the cytopathic effect associated with HIV 
replication, and therefore likely contribute to the long-lived 
viral reservoirs that impede viral eradication. This suggests 
that selective impairment of apoptosis in myeloid cells must 
occur by mechanisms unique to those cells. Evidence for 
this, though, is mixed, and varies based on what experimental 
conditions are used.
Early experiments with the promonocytic U937 cell line, 
and the myeloblastic PLB-985 cell line, when chronically 
infected with HIV, demonstrated that resistance of these 
cells to HIV-induced apoptosis was associated with consti-
tutive NF-κB activity in infected cells compared to unin-
fected cells. However, HIV-infected cells had an increased 
susceptibility to apoptosis induced by additional stimuli, 
such as TNF and the protein synthesis inhibitor cyclohex-
imide [42]. In contrast, chronically HIV-infected U937 cells 
are more resistant to apoptosis induced by DNA-damaging 
agents compared to uninfected cells or latently infected 
U937 cells [43]. However, activation of viral replication in 
the latently infected macrophages renders these cells also 
resistant to apoptosis induced by DNA-damaging agents, 
suggesting that viral proteins expressed in these cells may 
have predominately anti-apoptotic effects. This is important 
because current research aimed at eradication of latent viral 
reservoirs is predicated on the hypothesis that activating 
viral replication will increase susceptibility to apoptosis-
inducing agents. This may be a sound strategy for latently 
infected T cells, but this may not be the case in macrophages. 
In addition, chronically HIV-infected U937 cells are more 
resistant to apoptosis induced by hydrogen peroxide or the 
protein kinase inhibitor staurosporine compared to unin-
fected cells [44]. Induction of increased viral replication in 
these cells with TNF or PMA did not alter susceptibility to 
these apoptosis-inducers.
Chronically HIV-infected U937 cells exhibit a substan-
tially different apoptosis-related gene expression profile 
compared to chronically infected CD4 T cells lines (H9 and 
MT4), including differential expression of NME3, STK17A, 
CD74, and HIPK3 [5]. Similarly, circulating monocytes 
from HIV-infected donors exhibit differential expression of 
38 apoptosis-related genes compared to uninfected donors 
[45]. These genes, linked to p53, CD40L, TNF, and MAPK 
signaling pathways, are associated with increased resistance 
to FasL-induced apoptosis in monocytes from HIV-infected 
donors compared to uninfected donors.
In vitro HIV infection of cultured monocyte-derived 
macrophages (MDMs) results in production of TNF and 
NF-κB activation, and yet the cells do not die [46]. This 
resistance to apoptosis is associated with increased expres-
sion of Bcl2 and Bcl-XL, and decreased Bax expression. 
Since the increased expression of Bcl2 and Bcl-XL is not 
fully reversed by an NF-κB inhibitor, it is likely that HIV-
associated proteins modulate the expression of these proteins 
in macrophages as well in an NF-κB-independent manner. 
Another study in a similar model showed that in vitro HIV 
infection of MDMs also results in hyperphosphorylation of 
the pro-apoptotic protein Bad, resulting in its inactivation 
and consequent MDM resistance to HIV-induced apoptosis 
[47]. This effect was dependent on functional Nef expres-
sion, since infection of MDMs with a single deletion mutant 
pseudovirus lacking functional Nef resulted in significantly 
increased apoptosis compared to wild-type Nef [47]. On the 
other hand, in vitro HIV infection of MDMs also results in 
impaired NF-κB-dependent responses to TLR2 and TLR4 
agonists at a transcriptional level compared to uninfected 
cells [48]. Since these infected macrophages do not die 
during in vitro infection, this suggests that selective inhibition 
of NF-κB in these cells may preserve infected cell viability.
Immune evasion
In addition to avoiding HIV-induced infected cell death, 
it is hypothesized that anti-apoptotic effects of HIV infec-
tion may have evolved in order for the virus to evade the 
immune response to infection, either by evading detection 
of infected cells by innate censors, or by inducing resist-
ance of infected cells to the various death ligands used by 
immune effector cells to kill infected target cells.
For instance, both cytotoxic T lymphocytes and NK cells 
are important components of the innate immune response 
to HIV. NK cells express a class of receptors called killer 
cell immunoglobulin-like receptors (KIR), which interact 
with MHC Class I ligands, and can be either inhibitory or 
activating in antiviral activity [49, 50]. Effective killing 
of HIV-infected CD4 T cells by autologous NK cells is 
dependent on the type and activity of KIR expression on 
the NK cell and the type of MHC Class I expression on 
the target cell [51]. On the host side, numerous studies 
demonstrate that polymorphisms in the KIR and HLA 
loci are associated with variations in HIV control, disease 
progression, and immunologic recovery on antiretroviral 
therapy [52–54]. Furthermore, HIV has evolved a number of 
ways to circumvent these protective responses. As mentioned 
above, the HIV Nef protein downregulates the expression 
of MHC class I molecules on the surface of infected cells, 
which provides for one mechanism of evasion of recogni-
tion by cytotoxic T lymphocytes and NK cells [55]. In addi-
tion, HIV sequence polymorphisms that enhance inhibitory 
KIR activity are selected under the immunologic pressure 
of KIR + NK cells in chronically HIV-infected individuals 
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[56]. These HIV mutations are then associated with reduced 
antiviral activity of the NK cells, adding another potential 
mechanism of immune escape.
Regarding resistance to death ligands, multiple investi-
gators have shown that stable expression of Nef in Jurkat T 
cells renders those cells less susceptible to Fas- and TNF-
induced apoptosis compared to control cells [57–59]. One 
mechanism for this appears to be that Nef binds to ASK-1 
(apoptosis signal-regulating kinase 1), preventing its dis-
sociation from thioredoxin, a requisite step in Fas and 
TNF receptor-mediated activation of JNK1 [59]. Notably, 
this effect was also demonstrated in HIV-infected primary 
CD4 T cells. Also, coculture of HIV-infected primary 
CD4 T cells with autologous macrophages resulted in a 
decrease in apoptotic infected cells through hyperactiva-
tion of NF-κB by TNF stimulation, an effect that was not 
present in cells infected with a single deletion Nef-mutant 
virus [57].
TRAIL is another death ligand used by innate immune 
effector cells to clear virally infected cells [9]. Monocytes 
prestimulated with exogenous Tat are more resistant to apop-
tosis induced by recombinant TRAIL compared to unstimu-
lated monocytes, an effect associated with increased Bcl-2 
expression [60]. Other effects of individual HIV proteins on 
TRAIL sensitivity have been discussed above. HIV-infected 
macrophages are resistant to TRAIL-mediated apoptosis 
[61]. This has been associated with increased macrophage 
colony-stimulating factor (M-CSF), decreased TRAIL-R1 
expression, and increased expression of the anti-apoptotic 
proteins Mcl-1 and Bfl-1 [61]. Furthermore, HIV-infected 
dendritic cells are resistant to TRAIL-dependent NK cell-
mediated killing [62]. This resistance in dendritic cells to 
TRAIL-induced apoptosis is associated with increased 
expression of c-FLIP and c-IAP2 in infected dendritic cells.
TRAIL resistance in HIV-infected cells is not limited 
to myeloid cells. Primary CD4 T cells from HIV-infected 
subjects are resistant to TRAIL-induced apoptosis by 
autologous plasmacytoid dendritic cells, despite expres-
sion of functional TRAIL on the dendritic cells and TRAIL 
receptors on the CD4 T cells [63]. In fact, we have shown 
that HIV-infected CD4 T cells, despite expression of 
functional TRAIL and TRAIL receptors, do not undergo 
TRAIL-dependent killing, since immunodepletion with an 
anti-TRAIL antibody does not inhibit HIV-induced apop-
tosis in vitro. HIV infection induces alternative splicing 
of the TRAIL message, producing a novel TRAIL splice 
variant—TRAIL-short (TRAIL-s)—that binds selectively 
to TRAIL-R2 but does not induce apoptosis [64]. Knock-
down of TRAILs in HIV-infected cells increases TRAIL 
sensitivity. Furthermore, TRAILs is detectable in serum and 
PBMCs of HIV-infected patients, suggesting that this anti-
apoptotic mechanism may contribute to immune evasion of 
HIV-infected cells in vivo.
Mutational escape of antiretroviral therapy
Inhibition of viral replication with antiretroviral therapy 
decreases HIV-induced apoptosis, and some antiretrovirals, 
particularly the protease inhibitors, have intrinsic anti-apop-
totic activity independent of their antiviral effects [65]. On 
the other hand, mutational escape of suppressive antiretrovi-
ral therapy, which results in breakthrough viral replication, 
does not always result in increased CD4 T cell apoptosis, 
suggesting other viral anti-apoptotic mechanisms in these 
rare situations. For instance, certain resistance mutations, 
which develop in the gp41 subunit of Env during treatment 
with enfuvirtide, are associated with a decreased ability to 
induce fusogenic apoptosis in bystander cells compared to 
the wild-type virus [66]. Likewise, we have described resist-
ance mutations in HIV protease that occur during treatment 
with protease inhibitors that impair the virus’ ability to pro-
duce an HIV-specific pro-apoptotic protein—Casp8p41—
compared to wild-type protease, and thereby decrease apop-
tosis in infected cells [67]. While the evolutionary benefit of 
these two effects is unclear, it is possible that the impaired 
ability to induce apoptosis in these mutant viruses is a com-
pensatory mechanism for the decreased replicative fitness 
induced by antiretroviral therapy.
Toward an HIV cure
Since the description of the “Berlin patient”, who appears 
to have been functionally cured after two myeloablative 
peripheral blood stem cell transplants including one from 
a donor with a CCR5 deletion, and the recent description 
of two HIV-infected patients with undetectable HIV DNA 
after reduced intensity conditioning peripheral blood stem 
cell transplants, there has been a resurgence in the efforts to 
find a cure for chronic HIV infection [68, 69]. These efforts 
largely rely on various methods including gene therapy, 
immune-based therapies, and targeted reactivation of latent 
virus. The intent of the latter is that newly productively 
infected cells will die via one of the number of pro-apop-
totic mechanisms implicated in HIV-induced cell death 
[70]. Unfortunately, however, accumulating evidence sug-
gests that reactivation of latent viral reservoirs alone does 
Table 1  A summary of anti-apoptotic mechanisms of HIV
Down-regulation of cell surface receptor expression
Alteration of intracellular protein expression levels, or the “apoptotic 
milieu”
Modulation of protein phosphorylation
Regulation of cell cycle progression
Evasion of innate and adaptive immune responses to infection
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not lead to infected cell death, and may actually increase 
viral burden [71, 72, 73]. This phenomenon is likely due to 
an HIV-induced anti-apoptotic state within the infected cell. 
Sensitization to pro-apoptotic stimuli, akin to chemothera-
peutic combination treatment of apoptotic-resistant cancer 
cells, may be the solution to this problem. For instance, 
stimulation of latently infected cultured central memory T 
cells with αCD3/αCD28 antibodies leads to effective deple-
tion of virally infected cells, whereas homeostatic signals, 
i.e., IL2 and IL7, leads to preservation of the infected cells 
[74]. An alternative strategy that has been explored in vitro 
is ex vivo antigenic stimulation of HIV-specific cytotoxic T 
lymphocytes to increase the CTL’s cytolytic effectiveness 
against reactivated cells [73].
Conclusions
While many questions remain, all evidence suggests that 
HIV has evolved a number of mechanisms to interrupt 
apoptotic signaling and alter the apoptotic susceptibility 
of infected cells in order to delay premature cell death and 
evade the immune response with the result of promoting 
viral replication and persistence through the establishment 
of a latent viral reservoir (Table 1). The pleomorphic pro- or 
anti-apoptotic attributes of several of the HIV viral proteins 
could potentially be explained by the timing of expression 
and relative intracellular concentrations during the viral life 
cycle (Fig. 1). Establishing which of these mechanisms iden-
tified in the varying in vitro models occur in HIV-infected 
patients, and discovering additional novel anti-apoptotic 
mechanisms, will be most important in advancing the search 
for a safe and effective eradication strategy.
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and reproduction in any medium, provided the original author(s) and 
the source are credited.
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